ATE286398T1 - Desmethylolanzapine enthaltende zusammensetzungen und verfahren - Google Patents
Desmethylolanzapine enthaltende zusammensetzungen und verfahrenInfo
- Publication number
- ATE286398T1 ATE286398T1 AT99960547T AT99960547T ATE286398T1 AT E286398 T1 ATE286398 T1 AT E286398T1 AT 99960547 T AT99960547 T AT 99960547T AT 99960547 T AT99960547 T AT 99960547T AT E286398 T1 ATE286398 T1 AT E286398T1
- Authority
- AT
- Austria
- Prior art keywords
- desmethylolanzapine
- disorder
- compositions
- olanzapine
- treatment
- Prior art date
Links
- FHPIXVHJEIZKJW-UHFFFAOYSA-N 4'-N-desmethylolanzapine Chemical compound S1C(C)=CC2=C1NC1=CC=CC=C1N=C2N1CCNCC1 FHPIXVHJEIZKJW-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 2
- 229960005017 olanzapine Drugs 0.000 abstract 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010017543 Fungal skin infection Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 230000016571 aggressive behavior Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000003001 depressive effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008406 drug-drug interaction Effects 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 208000016686 tic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10958498P | 1998-11-23 | 1998-11-23 | |
| PCT/US1999/027647 WO2000030650A1 (en) | 1998-11-23 | 1999-11-22 | Desmethylolanzapine compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE286398T1 true ATE286398T1 (de) | 2005-01-15 |
Family
ID=22328453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99960547T ATE286398T1 (de) | 1998-11-23 | 1999-11-22 | Desmethylolanzapine enthaltende zusammensetzungen und verfahren |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6348455B1 (https=) |
| EP (1) | EP1133300B1 (https=) |
| JP (1) | JP2002530341A (https=) |
| AT (1) | ATE286398T1 (https=) |
| AU (1) | AU757973B2 (https=) |
| CA (1) | CA2351718A1 (https=) |
| DE (1) | DE69923081T2 (https=) |
| ES (1) | ES2237188T3 (https=) |
| PT (1) | PT1133300E (https=) |
| WO (1) | WO2000030650A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200402289A (en) * | 2002-05-17 | 2004-02-16 | Wyeth Corp | Methods of treating gastrointestinary and genitourinary pain disorders |
| PL199016B1 (pl) | 2002-06-20 | 2008-08-29 | Adamed Sp Z Oo | Sposób wytwarzania olanzapiny |
| US6831077B2 (en) * | 2002-07-25 | 2004-12-14 | Comprehensive Neuroscience, Inc. | Augmentation of atypical antipsychotic agent pharmacotherapy with chromium supplementation |
| AU2003268026A1 (en) * | 2002-07-30 | 2004-02-16 | Peter Migaly | Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions |
| CN1989968B (zh) | 2002-12-27 | 2011-05-11 | 大塚制药株式会社 | 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂 |
| AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
| WO2004071417A2 (en) * | 2003-02-05 | 2004-08-26 | University Of Vermont And State Agricultural College | Inhibitors of candida albicans |
| PL198589B1 (pl) | 2004-11-22 | 2008-06-30 | Adamed Sp Z Oo | Sposób wytwarzania N-demetyloolanzapiny |
| WO2006081327A2 (en) * | 2005-01-25 | 2006-08-03 | University Of Vermont And State Agricultural College | Small molecules that reduce fungal growth |
| US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
| AU2008279572A1 (en) * | 2007-02-01 | 2009-01-29 | David Chau | Combinations of dopamine D2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4115568A (en) | 1974-11-26 | 1978-09-19 | Lilly Industries Limited | Thieno[3,2-b]-[1,5]benzodiazepines |
| US4590213A (en) * | 1983-04-08 | 1986-05-20 | Eli Lilly And Company | Anti-anxiety method |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5627178A (en) | 1991-04-23 | 1997-05-06 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| US5605897A (en) | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| US5457101A (en) | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
| AU7013196A (en) | 1995-09-29 | 1997-04-17 | Eli Lilly And Company | Method for treating a tic disorder |
| JP2000502346A (ja) | 1995-12-21 | 2000-02-29 | イーライ・リリー・アンド・カンパニー | 皮膚炎の処置方法 |
| PL327600A1 (en) | 1995-12-22 | 1998-12-21 | Lilly Co Eli | Method of treating depressions |
| UA57727C2 (uk) | 1996-03-11 | 2003-07-15 | Елі Ліллі Енд Компані | Спосіб лікування надмірної агресивності |
| CZ290498A3 (cs) | 1996-03-11 | 1999-10-13 | Eli Lilly And Company | Farmaceutický prostředek proti autistickým stavům |
| JP2000517287A (ja) | 1996-03-11 | 2000-12-26 | イーライ・リリー・アンド・カンパニー | 物質乱用の処置方法 |
| WO1997033577A1 (en) * | 1996-03-11 | 1997-09-18 | Eli Lilly And Company | Method for treating bipolar disorder |
| GB9615767D0 (en) | 1996-07-26 | 1996-09-04 | Smithkline Beecham Plc | Novel treatment |
-
1999
- 1999-11-22 PT PT99960547T patent/PT1133300E/pt unknown
- 1999-11-22 AT AT99960547T patent/ATE286398T1/de not_active IP Right Cessation
- 1999-11-22 WO PCT/US1999/027647 patent/WO2000030650A1/en not_active Ceased
- 1999-11-22 EP EP99960547A patent/EP1133300B1/en not_active Expired - Lifetime
- 1999-11-22 ES ES99960547T patent/ES2237188T3/es not_active Expired - Lifetime
- 1999-11-22 US US09/444,590 patent/US6348455B1/en not_active Expired - Fee Related
- 1999-11-22 DE DE69923081T patent/DE69923081T2/de not_active Expired - Fee Related
- 1999-11-22 AU AU17416/00A patent/AU757973B2/en not_active Ceased
- 1999-11-22 JP JP2000583533A patent/JP2002530341A/ja not_active Withdrawn
- 1999-11-22 CA CA002351718A patent/CA2351718A1/en not_active Abandoned
-
2001
- 2001-12-19 US US10/026,303 patent/US6468997B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69923081T2 (de) | 2005-12-08 |
| WO2000030650A1 (en) | 2000-06-02 |
| EP1133300B1 (en) | 2005-01-05 |
| US6348455B1 (en) | 2002-02-19 |
| US20020082251A1 (en) | 2002-06-27 |
| CA2351718A1 (en) | 2000-06-02 |
| AU757973B2 (en) | 2003-03-13 |
| AU1741600A (en) | 2000-06-13 |
| EP1133300A1 (en) | 2001-09-19 |
| DE69923081D1 (de) | 2005-02-10 |
| PT1133300E (pt) | 2005-04-29 |
| US6468997B2 (en) | 2002-10-22 |
| JP2002530341A (ja) | 2002-09-17 |
| ES2237188T3 (es) | 2005-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE253364T1 (de) | Olanzapin-n-oxide enthaltende pharmaceutische zusammensetzungen | |
| ATE286398T1 (de) | Desmethylolanzapine enthaltende zusammensetzungen und verfahren | |
| PT751939E (pt) | Naftilamidas como agentes para o sistema nervoso central | |
| BRPI0402420A (pt) | Processos de toner | |
| TW200503705A (en) | 3-amino chroman and 2-amino tetralin derivatives | |
| DE69631065D1 (de) | Verbessertes mittel zur verringerung des fliesswiederstandes von schlamm | |
| DE60237778D1 (de) | Antikörper gegen kdr, deren herstellung und verwendungen | |
| DE60001770D1 (de) | Verfahren zur Herstellung von eigenleitfähigen Copolymeren und damit hergestellte eigenleitfähige Copolymer-Verbindungen | |
| DE69626393D1 (de) | Spezifische oligonukleotide für hepatitis b virus | |
| DE60027077D1 (de) | Reinigungszusammensetzung zur Behandlung und/oder Verbesserung von Schuppen, Dermatitis seborrhoeica, Psoriasis und Ekzemen und deren Symptomen | |
| TR200101357T2 (tr) | Parkinson hastalığı, ADHD ve mikroadenomların tedavisi için ilaçlar. | |
| DE60103927D1 (de) | Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems | |
| DE69833645D1 (de) | Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen | |
| DE60231507D1 (de) | Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten | |
| ATE519859T1 (de) | Verfahren zur herstellung von ausgewählten intermolekularen quervernetzungen in nukleinsäuren und ihre verwendungen | |
| BR9910958A (pt) | Composição para cuidar de cabelo, e, processo para condicionar e conferir corpo ao cabelo | |
| DE69803909D1 (de) | Verfahren und Zwischenprodukte, die für die Herstellung von Antifolaten verwendbar sind | |
| BR0305381A (pt) | Composição cosmética, usos de uma composição e processo de lavagem e condicionamento dos cabelos | |
| NO995948D0 (no) | DNA-sekvenser, ekspresjon av disse DNA-sekvenser, termofile laccaser kodet for av DNA-sekvensene, samt anvendelse av disse | |
| Daube et al. | Translesion replication by DNA polymerase β is modulated by sequence context and stimulated by fork-like flap structures in DNA | |
| DE69810524D1 (de) | Polyethylenterephthalatharzzusammensetzung, geformtes Produkt und Modifikationsverfahren | |
| DE69927416D1 (de) | Globale regulatoren von pathogenen bakteriellen genen; bakterielles selbstinduzierendes inaktivierungsprotein, die als ziele für die herstellung von krankheitsresistenzen einsetzbar sind | |
| Mora | Mesillaros and Gringo Mexicans: The changing meanings of race, nation, and space in Southern New Mexico, 1848–1912 | |
| Laurent | The scent of music | |
| DE60109799D1 (de) | Verwendung von quetiapin für aufmerksamkeitsmangel-hyperaktivitätsstörungen oder verhaltensstörungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1133300 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |